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cells;
Uncontrolled severe
allergic asthmaMethods: In a double-blind, randomized, placebo-controlled study, patients with severe
allergic asthma uncontrolled by high dose inhaled corticosteroids and long-acting b2-agonist
received either omalizumab (nZ 20) or placebo (nZ 11) over 16 weeks at appropriate doses
and frequencies. Baseline and end of study (week 16) Fc3RI expression on basophils and plas-
macytoid dendritic cells was determined by flow cytometry for the primary endpoint.
Secondary efficacy endpoints included asthma control and lung function as part of an initial
investigation into the use of Fc3RI expression as a marker of response.
Results: In the omalizumab group, andwith respect to placebo, Fc3RI expressionwas significantly
reduced at end of study on basophils (82.6%, p< 0.01) and plasmacytoid dendritic cells (44.2%,
pZ 0.029). Fc3RI expression reduction was not found to be correlated with clinical response.
Conclusions: Long-term omalizumab treatment induced reduction of Fc3RI expression on circu-
lating basophils and plasmacytoid dendritic cells. These changes were not associated with those
of clinical features related to severe asthma, which does not support further investigation into
its use as a predictive marker of response.
Trial registration: The study was registered with ClinicalTrials.gov (identifier: NCT00454051) and
the European Clinical Trials Database, EudraCT (identifier: 2006-003591-35)
ª 2010 Published by Elsevier Ltd.Introduction
Atopy and asthma have long been associated, although the
causative relationship between aeroallergen sensitivity and
asthma is not fully understood.1,2 In the initial allergic
response, and several aspects of chronic inflammation,
immunoglobulin E (IgE) plays a key role. Its binding to the
IgE high-affinity receptor (Fc3RI) at the surface of mast
cells and basophils is pivotal for the release of pro-inflam-
matory mediators.3,4
Omalizumab (Xolair,[] Novartis Pharma SAS.), a human-
ized recombinant murine monoclonal anti-IgE antibody, was
designed to treat allergic asthma by reducing the circu-
lating pool of IgE able to bind to Fc3RI.5,6 In this regard,
omalizumab treatment is successful, resulting in a marked
reduction of free IgE.7e10 It is known that IgE is able to both
up- and down-regulate Fc3RI expression11 but also that
serum IgE is positively correlated with Fc3RI density on
basophils12 and dendritic cells.13 Consistent with this,
several studies have shown substantial reduction in
the density of Fc3RI expressed on circulating basophils8
and dendritic cells9 of atopic patients treated with
omalizumab.
Severe-persistent asthma, uncontrolled by inhaled
corticosteroids and long-acting b2-agonists
14 may be
considered different to mild-to-moderate asthma in several
regards including the prevalence of atopy.15e17 But,
although atopy is less often found in severe asthmatics than
in those with controlled asthma, positive skin-prick tests
have been found in approximately 60% of patients with
severe uncontrolled asthma.15 Omalizumab has demon-
strated efficacy in moderate-to-severe allergic asthma18e20
and more recently the INNOVATE study21 confirmed this
efficacy in patients with severe allergic asthma, uncon-
trolled by GINA step 4 treatment.14 Subsequent reports of
the INNOVATE study found that it was difficult to predict
clinical response from baseline factors22 and that free IgE
levels varied in function of omalizumab concentrations,
independently of response.10 The INNOVATE study did not
however investigate the effect of omalizumab on Fc3RI
expression, and previous investigations that have done sodid not consider the same patient group nor attempt to
correlate this with disease response.8,9
The present study aimed to further understand the
effects of omalizumab therapy in uncontrolled severe
persistent allergic asthma by investigating the changes in
the expression of Fc3RI on basophils and plasmacytoid
dendritic cells (pDC213,23) after 16-week treatment with
omalizumab in comparison with placebo. It was also a pilot
study to investigate the potential for Fc3RI to be used as
a predictive marker of response in such patients, thus
correlation between change and clinical response at 16
weeks was also assessed.Methods
The study was conducted according to the Declaration of
Helsinki, approved by the Bordeaux ethics committee
(Comite´ de Protection des Personnes), and all participants
gave written informed consent. The study was registered
with ClinicalTrials.gov (identifier:NCT00454051) and the
European Clinical Trials Database, EudraCT (identi-
fier:2006-003591-35).
Patients
Were consecutively enrolled; adults (18 years) with
severe persistent allergic asthma with the following char-
acteristics: FEV1<80% of predicted, frequent daily symp-
toms (4 days/week average) or nocturnal awakening (1/
week average), multiple severe asthma exacerbations (2),
severe asthma exacerbations requiring an unscheduled
medical intervention with systemic corticosteroid in the
past year, or hospitalization/emergency room for an
asthma exacerbation in the past year, high dose inhaled
corticosteroid >1000 mg beclometasone dipropionate or
equivalent and an inhaled long-acting b2-agonist, allergy to
a perennial allergen (positive prick skin test or in vitro
reactivity to a perennial aeroallergen, RAST), total serum
IgE level 30 to 700 IU/ml and suitable serum total IgE
level and weight according to omalizumab dosing tables.
Figure 1 Patient flow. All patients receiving one dose of
study medication with at least one post-dose efficacy assess-
ment were included in the Intent-To-Treat (ITT) population.
The patients with missing pre- and/or post-treatment
assessment(s) of Fc3RI expression were excluded from the ITT
Fc3RI analyzable population for the primary endpoint.
Abnormal laboratory result refers to serum IgE outside dosing
table for omalizumab and abnormal test procedure refers to
a technical issue with serum IgE determination.
1610 P. Chanez et al.Exclusion criteria included: Smoking history >20 pack-
years, asthma exacerbation within 4 weeks prior to
randomization, history of food or drug-related severe
anaphylactoid/anaphylactic reaction, elevated serum IgE
levels for reasons other than allergy, previous use of oma-
lizumab and uncontrolled chronic diseases including
cancer.
Study design
This randomized, placebo-controlled, double-blinded,
multi-centre study to assess the expression of Fc3RI on
blood basophils and pDC2 comprised an initial screening
visit to determine eligibility four weeks before the 16-week
add-on treatment phase. It was performed from December
2006 to March 2008; six centres participated, all were in
France. At screening and subsequent visits, asthma and
concomitant treatments were recorded. All concomitant
treatments were allowed; maintenance asthma treatment
was to remain unchanged throughout the study period.
Study drug dose was determined following the European
SmPC of omalizumab24 using total IgE measured at
screening and body weight at week 0 of treatment phase
(baseline). During the treatment phase, patients made
study visits at weeks 0, 4, 8, 12 and 16 (additional visits if
injection every 2 weeks was required). The primary efficacy
variable was change from baseline in Fc3RI expression on
blood basophils and pDC2 after the 16-week treatment
phase. Blood samples were taken at screening (or week
0 before study drug administration in case of technical issue
with the original sample) and at week 16 for this assess-
ment. Primary comparison concerned the treatment groups
in terms of reduction of Fc3RI expression on basophils, the
comparison regarding Fc3RI expression on pDC2 was
secondary to this.
Treatment groups were also compared with regard to
secondary efficacy variables. Kinetics of change in Fc3RI
expression on blood basophils and pDC2 was assessed in
patients of a sub-set of centres (nZ 3). For those receiving
treatment every two weeks, additional blood samples were
taken at week 2 and for all patients of the centres con-
cerned, at weeks 4, 8 and 12. Asthma symptoms were
recorded in a patient diary card issued at screening (along
with a peak flow meter) and that was reviewed at each
visit. Asthma control and change from baseline was inves-
tigated by the number of non-satisfied items of the first 6
defining acceptable control according to the French
National Agency for Accreditation and Evaluation in
Healthcare (ANAES ): daytime symptoms <4 days per week,
nighttime symptoms (awakening) <1 night per week,
normal physical activity (no impairment in daily activities),
mild and infrequent exacerbations (absence of treatment
with oral corticosteroids), no absence from work/school,
short-acting b2-agonist <4 doses/week. Physicians gave
overall assessment of treatment effectiveness at week 16.
Adverse events, independently of relation to study drug,
and asthma exacerbations were recorded at each visit.
Patients were centrally randomized to either omalizu-
mab or placebo at a ratio of 2:1, stratified by centre.
Omalizumab was supplied by Novartis Pharma SAS, as
a sterile, freeze-dried preparation. Placebo was a physio-
logical salt solution, administered according to the samescheme to respect the same dosing frequency and injected
volume. Study medications were stored in the Pharmacy
Department of each centre. Since reconstitution time and
viscosity are different for omalizumab and placebo, indi-
viduals independent of the investigator reconstituted
drugs. The nurse who injected the drug was instructed not
to inform the patient or investigator of facts likely to
unblind treatment.
Analysis of Fc3RI expression
Blood samples (5 ml, EDTA tubes) were to be maintained at
ambient temperature (strictly >10 C) and analyzed within
24 h of collection by the cellular immunology laboratory of
the Bordeaux teaching hospitals. Flow cytometry analysis
(FC-500, Beckman Coulter) was performed on 100 ml
samples using the mAbs: anti-CD123 PE (Becton Dickinson),
anti-BDCA2 FITC (Miltenyi Biotec) and isotype control IgG2b
APC (Clinisciences), or, anti-CD123 PE, anti-BDCA2 FITC and
anti-Fc3RI APC (Clinisciences). The proportion of Fc3RI-
positive cells and Fc3RI expression (mean fluorescence
intensity) were determined either on basophils or pDC2
gated according to phenotype (CD123þ/BDCA2, CD123þ/
BDCA2þ respectively).
Statistical analysis
Based on previously reported results8,9 and anticipating
probability of 0.9 that Fc3RI reduction would be greater in
the omalizumab group compared to placebo, 10 patients
would give power of 87% (Wilcoxon test, risk Z 0.05). An
additional 10 patients were included in the omalizumab
Table 1 Characteristics of the ITT population.
Omalizumab N Z 20 Placebo N Z 11 All patients N Z 31
Sex, n (%)
Male 6 (30) 6 (54.5) 12 (38.7)
Age, years
Mean (SD) 45.7 (13.30) 50.6 (16.31) 47.4 (14.37)
Median (range) 42.0 (23; 74) 56.0 (25; 74) 49.0 (23; 74)
Weight, kga
Mean (SD) 74.2 (16.74) 74.5 (15.35) 74.3 (16.00)
Median (range) 70.5 (50; 112) 80.0 (51; 98) 71.0 (50; 112)
Asthma duration, years
Mean (SD) 31.2 (18.69) 31.8 (19.17) 31.4 (18.55)
Median (range) 30.0 (3; 74) 26.0 (1; 59) 28.0 (1; 74)
FEV1, % of predicted value
Mean (SD) 61.3 (14.83) 66.6 (11.38) 63.2 (13.75)
Median (range) 64.2 (35; 79) 64.6 (50; 90) 64.6 (35; 90)
Total IgE, IU/mL
Mean (SD) 202.0 (129.12) 253.3 (189.03) 220.2 (151.96)
Median (range) 246.5 (29.0; 384.0) 216.0 (31.0; 602.0) 234.0 (29.0; 602.0)
Asthma treatmentsb, n (%)
Inhaled corticosteroid 20 (100) 11 (100) 31 (100)
Long-acting b2-agonists 20 (100) 11 (100) 31 (100)
Oral corticosteroids 3 (15)c 4 (36.4) 7 (22.6)c
Theophylline 1 (5) 1 (9.1) 2 (6.5)
Montelukast 8 (40) 4 (36.4) 12 (38.7)
Anticholinergics 6 (30) 6 (54.5) 12 (38.7)
Inhaled corticosteroid daily dose, mg BDP eq./dayd
Mean (SD) 3712 (1042.7) 3272 (1348.4) 3556 (1157.8)
Median (range) 4000 (2000; 6500) 4000 (2000; 6000) 4000 (2000; 6500)
Asthma exacerbations requiring systemic corticosteroids
in previous year, n
Mean (SD) 4.7 (3.33) 4.0 (2.90) 4.4 (3.15)
Median (range) 3.5 (2; 15) 3.0 (2; 12) 3.0 (2; 15)
Hospitalizations in previous year, n
Mean (SD) 0.9 (2.03) 0.3 (0.65) 0.6 (1.68)
Median (range) 0.0 (0; 8) 0.0 (0; 2) 0.0 (0; 8)
Total nights in hospital in previous year, n
Mean (SD) 15.7 (31.54) 14.0 (9.90) 15.3 (26.93)
Median (range) 3.0 (1; 80) 14.0 (7; 21) 4.0 (1; 80)
Emergency room visits in previous year, n
Mean (SD) 0.9 (1.42) 0.3 (0.65) 0.6 (1.23)
Median (range) 0.0 (0; 5) 0.0 (0; 2) 0.0 (0; 5)
Physician visits for urgent treatment in previous year, n
Mean (SD) 3.9 (2.94) 2.7 (1.42) 3.5 (2.57)
Median (range) 3.0 (0; 10) 2.5 (0; 5) 3.0 (0; 10)
Absenteeism from school or work in previous year (days)
Mean (SD) 49.4 (119.40) 0.6 (1.77) 33.8 (100.22)
Median (range) 3.0 (0; 365) 0.0 (0; 5) 0.0 (0; 365)
Hospitalizations in intensive care unit in previous
year e yes, n (%) 2 (10) None 2 (6.5)
Intubations/assisted ventilations in previous year e yes, n None None None
a Data obtained at visit 2 (baseline), all other data obtained at visit 1 (screening).
b That were to be maintained over study period.
c Does not included one subject who received hydrocortisone to prevent adrenal insufficiency that was not considered to be for asthma
treatment.
d Beclometasone dipropionate (BDP) equivalent: 1 mg BDP Z 1 mg budesonide propionate Z 0.5 mg fluticasone propionate.
Figure 2 Change in Fc3RI expression on basophils and plasmacytoid dendritic cells (pDC2) at the end of study relative to baseline.
The change in Fc3RI expression (mean fluorescence intensity, MFI) on (a) basophils and (b) pDC2 for individual patients in the
omalizumab and placebo groups are shown. Median values are indicated by a solid bar to the right of each plot. Difference between
median change found in omalizumab and placebo groups was statistically significant for (a) basophils p < 0.01 and (b) pDC2
p Z 0.029.
1612 P. Chanez et al.group to allow better estimation of efficacy and safety. All
patients receiving one dose of study medication with at
least one post-dose efficacy assessment were included in
the intent-to-treat (ITT) population. All patients with no
major protocol deviation were included in the per-protocol
population. The reference population for efficacy analysis
was the ITT population. The patients with missing pre- and/
or post-treatment assessment(s) of basophil Fc3RI expres-
sion were excluded from the ITT and per-protocol pop-
ulations analyzable for the primary endpoint. Adverse
events were recorded for all patients receiving at least one
dose of study medication with at least one post-dose safety
assessment.
For the primary efficacy variable, change form baseline
(week 0 of treatment phase) was described by the differ-
ence between baseline value, defined for each patient as
the value observed at screening or at week 0 before the
first administration of study drug, and the value observed at
week 16, expressed as the % of baseline. Owing to the
method of measurement, statistical analyses were not
performed on absolute values. The treatment groups were
compared using the Wilcoxon non-parametric test.
Secondary efficacy variables including the comparison
between treatment groups of the change from baseline(month between screening visit and treatment phase) to
the last month of treatment in asthma symptoms, asthma
control and FEV1 were analyzed by the Wilcoxon test.
Correlation between asthma symptoms and Fc3RI expres-
sion (change from baseline) was analyzed using Spearman
rank correlation coefficients. However, the study was not
powered to detect a difference in secondary efficacy vari-
ables between omalizumab and placebo groups. Analyses
used two-sided tests with a 0.05 significance level.
Results
Demographic and baseline characteristics
Forty patients were screened, 31 were randomized (oma-
lizumab nZ 20, placebo nZ 11), and 25 (80.6%) completed
the study. Three patients discontinued in each treatment
group (15.0% in the omalizumab and 27.3% in the placebo
group). Analysis populations were intent-to-treat (ITT,
nZ 31) and those with initial and week 16 Fc3RI data were
included in the ITT Fc3RI analyzable (n Z 27, Fig. 1).
All patients were treated with high dose ICS in combi-
nation with a LABA, 22.6% (n Z 7) were also receiving oral
Table 2 Change from baseline Fc3RI expression (mean fluorescence intensity, MFI) and proportion (%) of basophils and
dendritic cells expressing Fc3RI after 4, 8, 12 and 16 weeks of treatment (patients with repeated measurements of the ITT Fc3RI
analyzable population).
Omalizumab N Z 8 Placebo N Z 4 p-value a
Fc3RI expression (MFI), % change from baseline, Median (range)
Basophils
Week 4 87.0 (92; 73) 37.7 (96; 12) 0.219
Week 8 81.6 (94; 67) 10.2 (50; 25) 0.008
Week 12 87.9 (95; 74) 31.0 (89; 54) 0.107
Week 16 90.0 (94; 82) 10.2 (23; 219) 0.011
Dendritic cells
Week 4 61.0 (81; 37) 37.8 (61; 9) 0.637
Week 8 35.9 (72; 36) 4.9 (64; 25) 0.799
Week 12 52.2 (81; 103) 21.5 (70; 57) 0.445
Week 16 53.9 (83; 6) 45.9 (37; 133) 0.108
% of cells expressing Fc3RI, change from baseline, Median (range)
Basophils
Week 4 1.8 (4; 19) 1.2 (18; 1) 0.777
Week 8 1.0 (4; 23) 1.3 (1; 2)) 0.669
Week 12 2.6 (24; 50) 1.3 (24; 1) 0.799
Week 16 1.0 (3; 21) 0.8 (6; 2) 0.395
Dendritic cells
Week 4 3.1 (78; 25) 3.2 (27; 15) 0.637
Week 8 0.8 (22; 25) 5.8 (2; 15) 0.203
Week 12 7.0 (49; 11) 1.6 (41; 26) 0.671
Week 16 11.2 (24; 9) 17.6 (0; 57) 0.018
a Wilcoxon test on change from baseline (post-hoc).
Omalizumab-induced decrease of Fc3RI expression 1613corticosteroids. In the year preceding the study, the mean
(SD) number of asthma exacerbations requiring systemic
corticosteroids and visits for urgent treatment were 4.4
(3.15) and 3.5 (2.57) respectively (Table 1).
Primary efficacy assessments
In the ITT-analyzable population and at end of study
(week 16) with regard to baseline (omalizumab n Z 16,
placebo n Z 11), the median change in Fc3RI expression
(mean fluorescence intensity, MFI) on basophils significantly
decreased in the omalizumab group (82.6%, range
94;11%) compared to the placebo group (15.6%, range
71; 219%: p < 0.01) and decrease was found for all
patients. All-but-one (93.8%) of the patients treated with
omalizumab exhibited a reduction of Fc3RI expression
50%, whereas all-but-one (90.9%) of the patients treated
with placebo exhibited a reduction of <50%, no change or
increase (Fig. 2a). The median proportion of basophils
expressing Fc3RI also decreased in the patients of the
omalizumab group (0.9%, range 13; 21%) compared to
those of the placebo group (1.0%, range 6; 15%), but this
was not found to be statistically significant (p Z 0.199).
In the ITT-analyzable population with data regarding
pDC2 (omalizumab n Z 15, placebo n Z 11), the median
change in the level of Fc3RI expression (MFI) was also
significantly decreased in the omalizumab group (44.2%,
range 83; 49) compared to the placebo group (13.6%,
range 60; 225%: p Z 0.029). The proportion of patientsexhibiting a reduction of Fc3RI 50% was 43.8% (n Z 7) in
the omalizumab group and 18.2% (n Z 2) in the placebo
group (Fig. 2b). The median proportion of pDC2 expressing
Fc3RI significantly decreased in the omalizumab group
(11.2, range 50; 68) compared to the placebo group
(6.4%, range 11; 57%: p Z 0.02).
In the omalizumab group, 7 patients (43.8%) exhibited
a reduction 50% in Fc3RI expression on both cell types
(basophils and pDC2), 8 (50%) on basophils only and none on
pDC2 only. Thus, all patients exhibiting such a reduction
on dendritic cells also exhibited this on basophils. Reduc-
tion in the proportion of cells expressing Fc3RI was found on
both cell types in 6 patients (37.5%), on basophils only in 2
patients (12.5%) and on pDC2 only in 3 patients (18.8%). In
the placebo group, reduction 50% in Fc3RI expression on
both cell types was found in one patient (9.1%) and on pDC2
only in one patient (9.1%). Reduction in the proportion of
cells expressing Fc3RI was found on both cell types in one
patient (9.1%), basophils only in 2 patients (18.2%) and
pDC2 only in 2 patients (18.2%).
Secondary efficacy assessments
In the sub-group of the ITT-analyzable population with
repeated Fc3RI measurements (at weeks 4, 8, 12 and 16),
reduction of Fc3RI expression on basophils in the omalizu-
mab group was present as early as week 4 and statistically
significant compared to the placebo group at weeks 8 and
16 (post-hoc analysis). There was no significant effect on
Table 3 Baseline values and changes from baseline at end of study in data obtained from patient diary card (ITT population).
Omalizumab N Z 20 Placebo N Z 11 P-valuea
Number of days with asthma symptoms per week
Baseline valueb, median (range) 7 (2; 7) 4.5 (1; 7) 0.140
Change from baseline at end of studyc, median (range) 1.4 (7; 3) 0.0 (4; 2)
Number of puffs of rescue SABA per week
Baseline valueb, median (range) 6.5 (0; 87) 3.8 (0; 45) 0.477
Change from baseline at end of studyc, median (range) 1.0 (45; 17) 0.0 (22; 4)
Number of nights with awakening per week
Baseline valueb, median (range) 2.1 (0; 7) 1.0 (0; 7) 0.405
Change from baseline at end of studyc, median (range) 0.6 (6; 1) 0.3 (4; 2)
Number of days with impairment in daily activities per week
Baseline valueb, median (range) 5.7 (0; 7) 4.0 (1; 7) 0.740
Change from baseline at end of studyc, median (range) 0.4 (7; 2) 0.3 (7; 2)
Number of days with absence from work or school per period
Baseline valueb, median (range) 0.0 (0; 28) 0.0 (0; 28) 0.083
Change from baseline at end of studyc, median (range) 0.0 (10; 0) 0.0 (0; 1)
Number of days with hospitalization per period
Baselineb None None NA
End of studyc None None
Number of unscheduled visits per period
Baseline valueb, median (range) 0.0 (0; 2) 0.0 (0; 1) 0.402
Change from baseline at end of studyc, median (range) 0.0 (2; 1) 0.0 (1; 1)
Morning daily PEF
Baseline valueb, median (range) 294.7 (125; 579) 311.0 (219; 482) 0.654
Change from baseline at end of studyc, median (range) 0.3 (79; 166) 14.2 (51; 55)
a Wilcoxon rank-sum test on change from baseline.
b Baseline: month between screening visit and treatment phase.
c End of study: month before last non-missing post-dose assessment.
1614 P. Chanez et al.the proportion of basophils expressing Fc3RI, no early effect
on the expression of Fc3RI on pDC2, nor on the proportion of
such cells expressing Fc3RI (Table 2).
In the ITT population, the change in asthma symptoms
from baseline to end of study (last non-missing post-dose
assessment) found better improvement in the omalizumab
group compared to the placebo group for all symptoms
explored except use of rescue SABA and morning PEF, butFigure 3 Fc3RI expression (MFI) on basophils in response to tre
(ITT Fc3RI analyzable population). Filled squares: omalizumab res
(n Z 9), filled circles: placebo responders (n Z 3), empty circles:no difference was found to be statistically significant
(Table 3). No correlation was found between asthma
symptoms and change from baseline at end of study of
Fc3RI expression on basophils and pDC2: Spearman corre-
lation coefficients ranged from 0.021 to 0.28, and p-values
from 0.91 to 0.16.
At the end of study, 5 patients in the omalizumab group
(25%) and one in the placebo group (9.1%) had anatment in physician evaluated responders and non-responders
ponders (n Z 6), empty squares: omalizumab non-responders
non-responders (n Z 6).
Table 4 Adverse events (ITT population).
Omalizumab N Z 20 n (%) Placebo N Z 11 n (%)
Total number of patients with
adverse events, n (%)
11 (55) 7 (63.6)
Number of serious adverse
events
0 1 (9.1)
Primary system organ class affected, n (%)
Infections and infestations 8 (40) 4 (36.4)
Gastrointestinal disorders 5 (25) 1 (9.1)
Nervous system disorders 3 (15) 1 (9.1)
General disorders and
administration site
conditions
3 (15) 0
Musculoskeletal and
connective tissue disorders
2 (10) 1 (9.1)
Eye disorders 1 (5) 1 (9.1)
Skin and subcutaneous tissue
disorders
0 1 (9.1)
Preferred term
Headache 3 (15) 1 (9.1)
Rhinitis 3 (15) 1 (9.1)
Gastrooesophageal reflux
disease
2 (10) 1 (9.1)
Back pain 2 (10) 0
Chills 2 (10) 0
Fatigue 2 (10) 0
Nausea 2 (10) 0
Viral infection 2 (10) 0
Bronchitis 1 (5) 1 (9.1)
Conjunctivitis 1 (5) 1 (9.1)
Abdominal pain upper 1 (5) 0
Acute sinusitis 1 (5) 0
Influenza 1 (5) 0
Myalgia 1 (5) 0
Sinusitis 1 (5) 0
Tonsillitis 1 (5) 0
Vomiting 1 (5) 0
Arthralgia 0 1 (9.1)
Dizziness 0 1 (9.1)
Nasopharyngitis 0 1 (9.1)
Oral fungal infection 0 1 (9.1)
Urticaria 0 1 (9.1)
Other clinically significant adverse events, n (%)
Exacerbation-related serious
adverse events
0 1 (9.1)
Discontinued due to asthma
exacerbation
1 (5) 2 (18.2)a
Preferred terms are ordered by descending frequency in omalizumab column. A subject with multiple occurrences of an AE under one
treatment was counted only once in the AE category for that treatment.
a One was qualified as serious adverse event.
Omalizumab-induced decrease of Fc3RI expression 1615acceptable/optimal control of asthma (defined by an
ANAES score of 0), none had such control at baseline. The
median (range) change from baseline values of FEV1 at
the end of study (last non-missing post-dose assessment) in
the ITT population was 2.6% (10; 60) in the omalizumab
group and 1.7% (19; 7) in the placebo group, but
this difference was not statistically significant (pZ 0.312).
The proportion of patients with no exacerbation wasrespectively 45% and 63.6% in the omalizumab and placebo
groups.
In the ITT population with available data for physician’s
overall assessment of treatment effectiveness at week 16
(omalizumab group nZ 17, placebo nZ 9), the proportion
of responders (response: excellent/good) was 47% (n Z 8)
in the omalizumab group and 33.3% (nZ 3) in the placebo.
Post-hoc analysis in the population with both data sets
1616 P. Chanez et al.(n Z 24) found that omalizumab reduced Fc3RI expression
in both responders and non-responders (Fig. 3).
Adverse events
Adverse events concerned 11 (55%) of the omalizumab
group and 7 (63.6%) of the placebo group, 1 subject of the
omalizumab group and 2 of the placebo group discontinued
due to asthma exacerbation. One subject of the placebo
group experienced an exacerbation-related serious adverse
event (Table 4).
Discussion
This double-blind, placebo-controlled study showed that at
16 weeks from initiation of omalizumab treatment Fc3RI
expression on basophils was significantly reduced in
patients with severe uncontrolled asthma. To a lesser
extent, but still significantly with respect to placebo, this
was also found on plasmacytoid dendritic cells (pDC223).
Reduced Fc3RI expression was found on basophils in all
patients and on pDC2 in all-but-one patient, yet there was
no correlation between changes in Fc3RI expression and
clinical response.
MacGlashan et al. report substantial reduction of Fc3RI
expression on basophils (z97%), but comparison is difficult
owing to the higher omalizumab dosing regimen than that
used in the current study.8 More recent studies did however
use the currently recommended dosing regimen (0.016 mg/
kg/IU[IgE]/mL per month). In studies of 6 weeks in dura-
tion, Lin et al. report a 73% median reduction of Fc3RI
expression on basophils7 and Prussin et al., a 75% median
reduction on pDC2.9 Both studies found a correlation of
Fc3RI expression with levels of free serum IgE. These results
seem to suggest that the effect of omalizumab was similar
on both cell types, however, Prussin et al. also investigated
basophils in parallel experiments and found that the
magnitude of Fc3RI reduction was greater in these than in
the dendritic cells tested. Further analysis of data pre-
sented by the authors finds that, as in the current study, all
patients exhibiting a 50% reduction of Fc3RI expression on
pDC2 (and pDC1) also exhibited such a reduction on baso-
phils but not the converse.9 Reduction of Fc3RI expression
on basophils and dendritic cells is reported to be rapid and
to reach maximal value within one month of treatment7e9
(but this may not be the case for mast cells25). The
kinetics of Fc3RI expression reduction reported herein for
a sub-group of patients are concordant with these results;
remaining relatively stable for both basophils and pDC2
cells over the course of the study following an initial
reduction within the first 4 weeks of treatment. It is yet to
be determined whether increased treatment duration (>16
weeks) would further reduce Fc3RI expression or alter the
differential effect found between cell types.
The overall incidence of adverse events was slightly
higher in the placebo group. All adverse events were as
expected for this patient population and pharmacological
class. No serious adverse events were reported in the
omalizumab group. With respect to the placebo group, in
the omalizumab group control was attained by more
patients and clinical markers were found to improve. Thelatter was not found to be statistically significant at the end
of the study, which was not powered to detect clinical
difference. Change in asthma symptoms were not corre-
lated with reduction of Fc3RI expression, despite this being
significant and widespread on both basophils and pDC2
cells. Interestingly, the INNOVATE study found a similarly
widespread effect on free IgE levels in the omalizumab
group and furthermore this concerned both drug responders
(99%) and non-responders (98%).10 Using the same measure
of response (physician’s overall assessment, validated using
INNOVATE data22) post-hoc analysis found a similar situa-
tion for Fc3RI expression on basophils. This suggests the
presence of a sub-population of patients clinically resistant
to the biological effects of omalizumab,21,22 although the
sample size limits somewhat the strength of such a conclu-
sion. One caveat is that although omalizumab has been
reported to modify lung tissue with respect to the media-
tors of allergic response in mild-to-moderate asthmatics26
and mild-intermittent asthmatics,27 only circulating cells
were investigated here. Independently of such limitations,
the widespread effect on Fc3RI expression reported here
does not support pursuit of investigation into its use as
a marker of response.
Taken together, the results presented here along side
those of the INNOVATE study, demonstrate that omalizu-
mab treatment in this population with difficult-to-treat
asthma is effective in reducing free IgE and induces
a reduction of Fc3RI expression on circulating basophils and
pDC2 as previously proposed.28 The finding that, as for free
IgE levels, reduction of Fc3RI expression was widespread in
treated patients but that not all of these responded to
treatment does not support further investigation of Fc3RI as
a predictive marker of response.Acknowledgements
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